What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Good Laboratory Practices for Clinical Labs: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Good Laboratory Practices in Clinical Labs

Good Laboratory Practices (GLP) constitute a formalized quality system that governs the organizational processes, environmental conditions, and operational procedures under which laboratory studies are planned, performed, monitored, recorded, archived, and reported. In clinical laboratories, GLP serves as the operational backbone that ensures diagnostic results are reliable, reproducible, and defensible—whether those results inform a physician's treatment decision, a clinical trial enrollment determination, or a public health surveillance report.

What is GLP?

GLP is a set of principles originally codified by the US Food and Drug Administration (FDA) in 1978 (21 CFR Part 58) in response to widespread deficiencies in nonclinical safety testing. The framework was subsequently adopted internationally through the Organisation for Economic Co-operation and Development (OECD) GLP guidelines, which now serve as the harmonized standard across Europe, Asia, and the Americas. While GLP historically applied to nonclinical safety studies, clinical laboratories have adopted these principles—alongside regulations specific to clinical diagnostics such as the Clinical Laboratory Improvement Amendments (CLIA) in the US and ISO 15189 internationally—to ensure the integrity of patient testing.

The scope of GLP in a clinical lab extends beyond the analytical run itself. It encompasses the entire testing lifecycle: pre-analytical processes (specimen collection, transport, and preparation), analytical processes (instrument operation, reagent handling, and measurement), and post-analytical processes (result verification, reporting, and interpretation). GLP also governs the supporting infrastructure: personnel qualifications, training documentation, equipment maintenance, environmental monitoring, and data management.

The distinction between GLP and routine quality control is important. Quality control (QC) refers to the operational techniques used to verify that a specific analytical run meets acceptance criteria. GLP is the broader system that ensures QC itself is performed correctly, documented properly, and acted upon when failures occur. In short, GLP is the quality system that makes QC meaningful.

Regulatory Bodies and Standards

Clinical laboratories operate under a layered regulatory framework. In the United States, the Centers for Medicare & Medicaid Services (CMS) administers CLIA, which mandates that laboratories performing testing on human specimens for diagnosis, prevention, or treatment must be certified. CLIA regulations (42 CFR Part 493) specify requirements for personnel qualifications, QC procedures, proficiency testing, and inspections. The FDA regulates in vitro diagnostic devices (IVDs) and, in the context of laboratory-developed tests (LDTs), has increasingly asserted oversight.

Internationally, ISO 15189:2022 (Medical laboratories—Requirements for quality and competence) is the primary standard for clinical laboratory quality management. It incorporates GLP principles while adding specific requirements for medical laboratory practice, including clinical risk management, point-of-care testing, and laboratory information system validation. The College of American Pathologists (CAP) accreditation program also incorporates GLP principles and adds peer-reviewed inspection criteria.

The practical implication is that a clinical lab must simultaneously satisfy multiple frameworks. A lab performing molecular diagnostics for oncology, for example, must comply with CLIA for operational certification, CAP for accreditation, and GLP principles for data integrity—especially if results feed into FDA-regulated clinical trials. Understanding which framework takes precedence in a given context is essential for designing compliant workflows.

Core Principles of GLP in Clinical Diagnostics

Personnel and Training

The most critical variable in laboratory quality is human performance. GLP requires that each individual in the laboratory has documented education, training, and experience commensurate with their assigned responsibilities. This is not a one-time requirement; it demands ongoing competency assessment and continuing education.

For a clinical molecular diagnostics lab, this means a technologist performing PCR-based assays must have documented training in nucleic acid extraction, amplification setup, amplicon handling, and contamination avoidance. Training records must include the date of training, the trainer's identity, the specific procedures covered, and evidence of competency—typically a combination of written assessment and observed performance. Competency must be re-evaluated at least semiannually during the first year and annually thereafter, per CLIA requirements.

Personnel files must also document continuing education, corrective action for performance deficiencies, and any changes in job responsibilities. A common GLP deficiency is the failure to update training records when procedures change. If a lab modifies its DNA extraction protocol from a manual column-based method to an automated magnetic-bead system, every operator must be retrained and re-documented before running patient samples.

Facility and Environmental Controls

The physical environment of a clinical lab directly affects analytical performance. GLP requires that facilities are designed and maintained to prevent contamination, ensure operator safety, and support stable instrument operation. Key environmental parameters include temperature, humidity, and air pressure differentials.

For molecular diagnostics, the most critical environmental control is the separation of pre-amplification and post-amplification areas. PCR is exquisitely sensitive to contamination by amplicons from previous reactions; a single copy of a previously amplified product can generate false-positive results. The standard design uses physically separate rooms or dedicated biosafety cabinets with unidirectional workflow: nucleic acid extraction and PCR setup occur in a clean room with positive air pressure, while amplification and product detection occur in a separate area with negative air pressure. Technologists must not move from post-amplification to pre-amplification areas without changing gowns and gloves.

Temperature and humidity monitoring is equally important. Many clinical analyzers have specified operating ranges—typically 15–30°C for ambient temperature and 20–80% relative humidity. Enzymatic reactions, including reverse transcription and polymerase chain reaction, are temperature-sensitive; a drift of even 2°C during the annealing step can alter primer binding specificity. Laboratories should use continuous monitoring systems with alarms and document daily temperature and humidity readings. Refrigerators and freezers storing reagents and specimens require the same continuous monitoring, with acceptance ranges defined by the manufacturer's stability data.

Quality Control and Quality Assurance in Clinical Labs

Internal Quality Control

Internal quality control (IQC) involves the daily analysis of control materials alongside patient samples to verify that the analytical system is performing within defined acceptance criteria. Control materials are commercially prepared samples with known concentrations of the analyte, or in the case of molecular assays, known genetic sequences.

For a quantitative PCR assay measuring HIV-1 viral load, the IQC strategy typically includes a negative control (no template), a low-positive control near the assay's limit of detection, and a high-positive control near the upper linear range. These controls are processed through the entire workflow—extraction, amplification, and detection—to verify that each step performed correctly. The low-positive control is particularly important because it detects subtle losses in analytical sensitivity that might otherwise go unnoticed.

IQC results must be evaluated using statistical process control. Levey-Jennings charts plot control values over time, with the mean and standard deviation (SD) calculated from at least 20 data points collected over 20–30 separate runs. Westgard multi-rules are then applied to interpret the chart: a single control value exceeding the mean ±2SD triggers a warning, while a value exceeding ±3SD, or two consecutive values exceeding the same ±2SD limit, triggers rejection of the run. The 1:2s rule (one control exceeding 2SD) is a warning; the 1:3s, 2:2s, R4s (range of 4SD between two controls), 4:1s (four consecutive values on the same side of the mean), and 10x (ten consecutive values on the same side of the mean) rules indicate systematic or random error requiring investigation.

The frequency of IQC depends on the assay and regulatory requirements. CLIA mandates that quantitative assays include at least two levels of control per run, while qualitative assays require both a negative and positive control. For high-throughput automated analyzers, controls must be run at least once per 24 hours, and additionally after calibration, after major maintenance, or when reagent lots change.

External Quality Assessment

External quality assessment (EQA), also known as proficiency testing (PT), evaluates the laboratory's performance against peer laboratories using blinded specimens. A proficiency testing provider distributes samples with unknown values to participating laboratories; each lab tests the samples using its routine methods and reports results. The provider then evaluates results against the reference value or the consensus of peer labs using the same method.

For molecular assays, PT panels typically include samples spanning the clinically relevant range, including near-threshold concentrations. For example, an HIV-1 RNA PT panel might include samples at 50, 500, 5,000, and 50,000 copies/mL. The laboratory's results are scored against acceptance criteria—for viral load assays, typically within ±0.5 log10 copies/mL of the expected value.

CLIA requires that laboratories participate in PT for each regulated analyte at least twice per year. Failure to pass PT—defined as scoring less than 80% for a single analyte or less than 100% for two consecutive events—triggers mandatory corrective action and potential suspension of testing for that analyte. Beyond regulatory compliance, EQA provides an independent check on the entire testing process, including lot-to-lot reagent variability, operator technique, and calibration drift.

Documentation and Record Keeping

SOPs and Their Management

Standard operating procedures (SOPs) are the written instructions that define how every task in the laboratory is performed. A well-written SOP is unambiguous, detailed enough for a competent technologist to execute without prior verbal instruction, and includes acceptance criteria for the final result.

An SOP for a nucleic acid extraction procedure, for example, must specify the exact kit and catalog number, the specimen type and volume, the lysis buffer composition and incubation temperature (typically 56°C for 10 minutes for proteinase K digestion), the binding and washing conditions, and the final elution volume. It must also specify the expected DNA yield and purity (A260/A280 ratio between 1.8 and 2.0) and the action to take if these criteria are not met.

SOP management requires version control. Each SOP must have a unique identifier, an effective date, a review date (typically every 2 years), and an approval signature from the laboratory director. Superseded versions must be archived and retained for at least 2 years—or longer for tests used in clinical trials, where GLP requires retention for the duration of the study plus any applicable regulatory period. The current version must be accessible at the point of use; a technologist should never have to leave the bench to consult a procedure.

Data Integrity and ALCOA

Data integrity in clinical laboratories is governed by the ALCOA principles, which define the attributes that make data trustworthy:

Attributable: Every data point must be traceable to the individual who generated it. Electronic records must use unique user logins; paper records require signatures with dates.
Legible: Records must be permanently readable. Pencil is prohibited; errors are corrected with a single line strike-through, the correction, the date, and the initials of the person making the correction.
Contemporaneous: Data must be recorded at the time the activity occurs, not retrospectively. A common violation is recording QC results at the end of a shift rather than when the run was performed.
Original: The original record, whether paper or electronic, must be preserved. Photocopies are not acceptable substitutes for original records.
Accurate: Data must be free from errors and manipulation. This includes ensuring that calculations are verified and that transcription errors are caught through independent review.

For electronic records, GLP requires that laboratory information systems (LIS) and instrument software have audit trails that capture every data entry, modification, and deletion, including the user identity, timestamp, and reason for change. The system must prevent unauthorized access through password controls and role-based permissions. For Good Laboratory Notebook Practices, the same principles apply to paper notebooks, where page numbers must be sequential, and blank spaces must be marked "intentionally left blank."

Equipment Maintenance and Calibration

Qualification and Validation

Equipment used in clinical testing must be qualified before it is placed into service and re-qualified after major repairs or relocation. Qualification follows a four-stage process:

Design Qualification (DQ): The user defines the functional and performance requirements for the instrument. For a real-time PCR instrument, this includes thermal accuracy (±0.5°C), ramp rate, optical detection sensitivity, and throughput.
Installation Qualification (IQ): The instrument is installed according to manufacturer specifications, and documentation verifies that utilities (electrical supply, network connectivity, ventilation) meet requirements.
Operational Qualification (OQ): The instrument is tested to verify that it operates within its specified parameters. For a thermal cycler, this involves measuring temperature uniformity across the block using a calibrated thermocouple probe—typically ±0.5°C at 95°C and ±0.4°C at 55°C.
Performance Qualification (PQ): The instrument is tested using known samples to verify that it produces accurate and precise results in the hands of laboratory personnel.

After qualification, instruments require ongoing calibration. Calibration establishes the relationship between the instrument's measurement and a known reference standard. For a pipette, calibration involves gravimetric measurement of dispensed water volume at multiple setpoints (typically 10%, 50%, and 100% of nominal volume). Acceptance criteria for a 100 µL pipette are typically ±1.0% accuracy and ±0.5% precision (coefficient of variation). Calibration must be performed at defined intervals—typically every 3–6 months for pipettes used in molecular assays—and after any event that could affect performance, such as a drop or repair.

Preventive Maintenance

Preventive maintenance (PM) is scheduled servicing performed to prevent instrument failure and maintain performance within specifications. PM schedules are defined by the manufacturer and must be documented in the instrument's maintenance log. For a real-time PCR instrument, PM includes cleaning the optical components, checking the heating block for debris, verifying the calibration of the fluorescence detection system, and replacing fuses or filters as needed.

The maintenance log must record the date, the technician's name, the specific tasks performed, any parts replaced, and the instrument's operational status after maintenance. If maintenance reveals a problem that could have affected patient results, the laboratory must evaluate all results generated since the last acceptable calibration or QC event—a process called "look-back." This evaluation must be documented and may require notifying clinicians if any results are suspect.

Sample Management and Chain of Custody

Pre-analytical Variables

The pre-analytical phase is the largest source of error in clinical laboratories, accounting for an estimated 60–70% of all laboratory errors. GLP requires that specimen collection, handling, and processing be controlled and documented to minimize these errors.

For molecular diagnostics, pre-analytical variables are particularly consequential. RNA is labile; an HIV-1 viral load test performed on a specimen that sat at room temperature for 6 hours before processing will yield falsely low results due to RNA degradation. The standard requirement is that whole blood for viral load testing must be processed to plasma within 4 hours of collection, or the specimen must be collected in a tube containing an RNA stabilizer such as EDTA with a proprietary preservative that stabilizes nucleic acids for up to 72 hours at room temperature.

Specimen labeling is a critical control point. Every specimen must have a unique identifier—typically a barcode—that links it to the patient's medical record. The label must include at least two patient identifiers (e.g., name and date of birth) and the date and time of collection. The laboratory must have a procedure for verifying that the specimen received matches the test requisition; a mismatch must be resolved before testing proceeds.

Chain of Custody

Chain of custody (CoC) is a documented, unbroken trail that accounts for the location and handling of a specimen from collection through disposal. While CoC is mandatory for forensic and legal testing (e.g., drug testing, paternity testing), GLP principles recommend its application to any specimen where result integrity could be challenged.

A CoC form records, for each transfer of the specimen: the date and time, the individual releasing the specimen, the individual receiving the specimen, and the purpose of the transfer. Each individual must sign and date the form. The specimen must be sealed with a tamper-evident seal that is inspected at each transfer point.

For clinical trials, CoC is essential because the results may support regulatory submissions. A specimen collected at a clinical site, shipped to a central laboratory, and analyzed for a pharmacodynamic biomarker must have documentation at each step. The shipping records must include the transport conditions (temperature, time in transit) and confirmation that the specimen arrived intact.

Safety and Waste Management in Clinical Labs

Biosafety Levels

Clinical laboratories handle potentially infectious materials and must operate at a biosafety level (BSL) appropriate for the agents they handle. BSL-2 is the standard for clinical diagnostic laboratories, where work involves human blood, body fluids, or tissues that may contain pathogens such as HIV, hepatitis B virus, or Mycobacterium tuberculosis.

BSL-2 requirements include: restricted access to the laboratory, hand-washing sinks at exits, decontamination of work surfaces after each shift and after any spill, and the use of biological safety cabinets (BSCs) for procedures that generate aerosols—including vortexing, centrifugation, and pipetting of infectious materials. A Class II BSC with HEPA filtration is standard; the cabinet must be certified annually by a qualified technician and after any filter replacement or relocation.

Personal protective equipment (PPE) is mandatory: laboratory coats, gloves, and eye protection. Gloves must be changed between patient specimens and after any contact with potentially contaminated surfaces. Needles and sharps must be disposed of in puncture-resistant containers, and needle recapping is prohibited.

Chemical and Radioactive Waste

Clinical laboratories generate chemical waste—including organic solvents, acids, and staining reagents—that must be segregated, labeled, and disposed of according to environmental regulations. For example, xylene used in histology must be collected in a dedicated waste container and disposed of as hazardous waste; it cannot be poured down the drain. Each waste container must be labeled with the chemical name, the hazard class, and the accumulation start date.

Radioactive waste, generated by laboratories performing radioimmunoassays or using radiolabeled tracers, requires additional controls. The laboratory must have a radiation safety officer, a license from the Nuclear Regulatory Commission (or state equivalent), and a documented program for monitoring personnel exposure using dosimeters. Radioactive waste must be stored in shielded, labeled containers and disposed of through an authorized vendor.

The GLP requirement is that waste management procedures are documented in SOPs, that staff are trained in waste segregation, and that disposal records are retained. A common deficiency is the commingling of hazardous and non-hazardous waste, which can result in regulatory fines and, more importantly, create safety hazards for waste handlers.

Audits, Inspections, and Corrective Actions

Internal Audits

Internal audits are self-assessments conducted by the laboratory to verify compliance with its own SOPs, GLP principles, and regulatory requirements. The audit program should be risk-based: high-risk areas (e.g., molecular assays with high false-negative potential) are audited more frequently than low-risk areas.

An internal audit of the PCR workflow might examine: whether the pre-amplification and post-amplification areas are physically separated and that staff follow the required workflow; whether reagent lot numbers are recorded in the run log; whether QC results are reviewed and signed by the supervisor before patient results are released; and whether the thermal cycler maintenance log is current.

Audit findings are classified by severity. A critical finding (e.g., release of patient results without QC review) requires immediate corrective action. A major finding (e.g., expired reagents in use) requires correction within a defined timeframe. A minor finding (e.g., incomplete training records) requires correction before the next audit cycle. All findings must be documented, and the corrective actions must be verified for effectiveness.

Regulatory Inspections

Regulatory inspections—by CMS, CAP, or FDA—are unannounced or announced assessments of the laboratory's compliance. The inspector will review personnel files, SOPs, QC records, PT results, equipment maintenance logs, and patient result documentation. The inspector may also observe laboratory operations and interview staff.

Preparation for inspections is an ongoing process, not a last-minute activity. The laboratory should maintain a "ready state" where all records are current, all SOPs are approved and in effect, and all staff can articulate their responsibilities. During the inspection, the laboratory director or designee should accompany the inspector, provide requested documents promptly, and address questions honestly. If a deficiency is identified, the laboratory should acknowledge it, propose a corrective action, and implement it within the required timeframe.

The corrective and preventive action (CAPA) process is the mechanism for addressing audit and inspection findings. The process involves: (1) identifying the root cause of the deficiency (using tools such as the "5 Whys" or fishbone diagrams); (2) implementing a corrective action to eliminate the root cause; (3) verifying that the corrective action is effective; and (4) implementing preventive actions to prevent recurrence. For example, if an audit finds that QC results were not reviewed before patient results were released, the root cause might be that the LIS does not enforce a QC review gate. The corrective action would be to configure the LIS to block result release until QC is reviewed; the preventive action might be to add a monthly audit of result release workflows.

Common Pitfalls and How to Avoid Them

Inadequate Training

The most common GLP deficiency in clinical laboratories is inadequate training documentation. Technologists may be performing procedures competently, but if their training records do not document the specific procedure, the date, and the competency assessment, the laboratory is non-compliant. This is particularly problematic when procedures change: a lab may update its extraction protocol but fail to retrain and re-document all operators.

The solution is a structured onboarding and ongoing training program. Each new procedure must have a training checklist that includes: reading the SOP, observing a qualified trainer perform the procedure, performing the procedure under supervision, and demonstrating independent competency. The checklist must be signed and dated by both the trainee and the trainer, and the completed checklist must be filed in the trainee's personnel record.

Poor Documentation Practices

Documentation failures take many forms: recording results on scrap paper before transcribing to the official record, failing to date and sign entries, using correction fluid instead of single-line strike-throughs, and failing to record contemporaneous data. These practices undermine data integrity and can invalidate patient results.

The solution is to embed documentation into the workflow. Electronic systems should be used wherever possible, with barcode scanning for specimen identification and direct data capture from instruments. For paper-based processes, the laboratory should use bound notebooks with pre-numbered pages, require entries in permanent ink, and prohibit the use of scrap paper. The Duplicate Laboratory Notebook Best Practices and Electronic Notebook Table Best Practices provide additional guidance on maintaining compliant records.

Other Frequent Failures

Expired reagents: Reagents must be labeled with the date of receipt, the date of opening, and the expiration date. The expiration date is the earlier of the manufacturer's date or the date determined by the laboratory's stability studies after opening. A common failure is using a reagent past its open-date stability without documenting re-validation.
Calibration drift: Instruments may drift out of specification between scheduled calibrations. This is detected through QC, but only if QC is run at the required frequency and evaluated using Westgard rules. A lab that runs QC once per week on a high-volume analyzer may miss a drift that occurs mid-week.
Sample mix-ups: Mislabeling or misidentifying specimens is a critical error. The solution is a two-person verification for high-risk tests, barcode-based identification, and a procedure for resolving discrepancies before testing.
Failure to investigate QC failures: A QC failure that is repeated without investigation indicates a systemic problem. Each QC failure must be investigated, the root cause identified, and corrective action documented. Simply repeating the QC run without investigation is a GLP violation.

Frequently Asked Questions

What are good laboratory practices (GLP) in clinical labs?

Good Laboratory Practices in clinical labs are a set of principles and operational procedures that ensure the reliability, integrity, and traceability of diagnostic testing. They cover personnel training, facility and environmental controls, equipment maintenance and calibration, quality control, documentation, sample management, and safety. GLP ensures that every result released to a clinician is accurate, reproducible, and defensible.

Why are good laboratory practices important in clinical labs?

GLP is important because diagnostic results directly influence patient care decisions. An inaccurate result can lead to misdiagnosis, inappropriate treatment, or failure to treat a life-threatening condition. GLP also ensures that laboratory data can withstand regulatory scrutiny, whether from CLIA, CAP, or FDA inspections, and that results are legally defensible if challenged.

What are the key components of GLP in clinical laboratories?

The key components are: (1) qualified and trained personnel with documented competency; (2) controlled facilities with environmental monitoring and contamination prevention; (3) calibrated and maintained equipment; (4) internal quality control with statistical process control; (5) external quality assessment through proficiency testing; (6) comprehensive documentation including SOPs and data integrity per ALCOA principles; (7) controlled sample management with chain of custody; and (8) a corrective and preventive action system.

How do clinical labs implement GLP?

Implementation begins with a gap assessment against GLP requirements, followed by the development or revision of SOPs, training of personnel, and establishment of QC and documentation systems. Implementation is an ongoing process that requires regular internal audits, continuous training, and a culture of quality where every staff member understands their role in maintaining compliance.

What is the difference between GLP and GCP?

Good Clinical Practice (GCP) governs the conduct of clinical trials involving human subjects, focusing on ethical conduct, informed consent, and protection of participant rights. GLP governs the conduct of laboratory studies, focusing on data integrity and reliability. In a clinical trial, the laboratory testing of participant samples must comply with both GCP (for the trial context) and GLP (for the analytical quality).

What are common GLP violations in clinical labs?

Common violations include: inadequate or missing training documentation; failure to perform or document equipment calibration and maintenance; use of expired reagents; improper documentation practices (e.g., late entries, erasures); failure to investigate QC failures; inadequate environmental monitoring; and failure to maintain a complete chain of custody for specimens.

How often should clinical labs perform quality control?

The frequency depends on the assay and regulatory requirements. CLIA requires at least two levels of control per run for quantitative assays and both negative and positive controls for qualitative assays. For high-throughput automated analyzers, controls are typically run at least once per 24 hours, and additionally after calibration, after major maintenance, or when reagent lots change. Proficiency testing is required at least twice per year per regulated analyte.

Key Takeaways

GLP in clinical labs is a comprehensive quality system covering personnel, facilities, equipment, QC, documentation, and sample management—not merely a set of checklists.
The pre-analytical phase is the largest source of laboratory error; controlled specimen collection, labeling, transport, and processing are essential GLP components.
Data integrity under the ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate) is non-negotiable and must be enforced through both paper and electronic record systems.
Internal QC using Westgard multi-rules detects analytical drift, while external proficiency testing validates performance against peer laboratories.
Equipment qualification (DQ, IQ, OQ, PQ) and scheduled preventive maintenance are mandatory; calibration intervals must be defined and documented.
The CAPA process is the mechanism for converting audit findings and QC failures into systemic improvements, not just one-time fixes.
A "ready state" of continuous compliance—not last-minute preparation—is the only effective strategy for passing regulatory inspections.